Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith Tobin

Geriatric Medicine Livonia, MI Doctor of Osteopathy

NPI 1083611560 CMS profile 94616

28701 Plymouth Rd, Livonia, MI 48150

Open in the dashboard

General payments

$6,747

335 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keith Tobin of Livonia, MI is reported in the CMS Open Payments database as having received $6,747 across 335 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,293 57
2024 General $939 51
2023 General $937 49
2022 General $660 35
2021 General $928 54
2020 General $662 36
2019 General $1,329 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Tobin
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Keith Tobin were reported at $1,293. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Keith Tobin Geriatric Medicine median Middle half National median
2019 $1,329 $96 $28–$339 $163
2020 $662 $99 $28–$262 $114
2021 $928 $94 $27–$318 $132
2022 $660 $103 $34–$338 $149
2023 $937 $109 $39–$320 $160
2024 $939 $125 $36–$371 $164
2025 $1,293 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $847 37 payments
  2. GlaxoSmithKline, LLC. $738 41 payments
  3. AstraZeneca Pharmaceuticals LP $635 31 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $477 25 payments
  5. ITI, Inc. $472 22 payments
  6. Sunovion Pharmaceuticals Inc. $407 16 payments
  7. Janssen Pharmaceuticals, Inc $334 20 payments
  8. Lilly USA, LLC $312 19 payments
  9. Amgen Inc. $284 15 payments
  10. Pfizer Inc. $223 13 payments
  11. Other $2,019 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,717 334 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $514 32 payments
  2. CAPLYTA $450 21 payments
  3. VRAYLAR $442 25 payments
  4. APTIOM $391 15 payments
  5. XARELTO $317 19 payments
  6. AIRSUPRA $296 12 payments
  7. JARDIANCE $291 14 payments
  8. Repatha $268 14 payments
  9. AIMOVIG $227 12 payments
  10. GLYXAMBI $210 10 payments
  11. Other $5,335 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 174 drugs

Part D claims

12,898

Median for Family Practice: 1,826

Drug cost

$1,261,221

Median for Family Practice: $120,094

Branded share of claims

23.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 347 $249,713
Jardiance Empagliflozin Brand 214 $217,411
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 78 $86,624
Ozempic Semaglutide Brand 58 $74,884
Xarelto Rivaroxaban Brand 85 $71,076
Farxiga Dapagliflozin Propanediol Brand 96 $70,355
Rybelsus Semaglutide Brand 21 $45,385
Entresto Sacubitril/Valsartan Brand 29 $35,756
Invokana Canagliflozin Brand 16 $19,893
Mounjaro Tirzepatide Brand 15 $18,052

The 10 drugs with the highest cost, of 174 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$52,703

Of which drugs: $3,122

Medicare patients

316

Average age 79

Services billed

1,404

181 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Alzheimer's or dementia 40%
Diabetes 39%
Depression 39%
Ischemic heart disease 33%
Heart failure 26%
Chronic kidney disease 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 21 21 $758

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $185
$185 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $131
$131 214 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $116
$116 78 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $98
$98 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $44
  • Lundbeck LLC $17
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record